• Molecular NameNalbuphine
  • SynonymNA
  • Weight357.45
  • Drugbank_IDDB00844
  • ACS_NO20594-83-6
  • Show 2D model
  • LogP (experiment)1.939
  • LogP (predicted, AB/LogP v2.0)1.98
  • pka8.71, 9.96
  • LogD (pH=7, predicted)0.56
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.32
  • LogSw (predicted, AB/LogsW2.0)0.79
  • Sw (mg/ml) (predicted, ACD/Labs)0.44
  • No.of HBond Donors3
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA73.16
  • StatusFDA approved
  • Administrationintravenous, intramuscular, subcutaneous
  • PharmacologyA synthetic opioid used commercially as an analgesic under a variety of trade names, including Nubain.
  • Absorption_value100.0
  • Absorption (description)The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.
  • Caco_2N/A
  • Bioavailability7.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include primarily sleepiness and mild dysphoria.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A